ModifiedUnitedHealthcarePolicy CS086KY.11

Occipital Nerve Injections and Ablation (Including Occipital Neuralgia and Headache) (for Kentucky Only)

Policy governing medical necessity and coverage for occipital nerve injections, blocks, neurostimulation, surgical procedures, and ablation for occipital neuralgia and related headaches for UnitedHealthcare members in Kentucky.

Policy Summary

PayerUnitedHealthcare

PolicyOccipital Nerve Injections and Ablation (Including Occipital Neuralgia and Headache) (for Kentucky Only)

Policy CodePolicy CS086KY.11

Change TypeMaterial revisions and code removal

Effective DateNov 1, 2024

Next Review DateN/A

Key ActionFor occipital nerve ablation for severe cancer pain, use InterQual CP: Procedures, Neuroablation, Percutaneous for medical necessity determinations.

SourceLink

POLICY UPDATE CHANGES

Removed language indicating occipital nerve ablation (destruction by neurolytic agent) is proven and medically necessary for treating pain due to malignancy involving the head and neck.

Updated instruction to refer to the InterQual ® CP: Procedures, Neuroablation, Percutaneous for medical necessity clinical coverage criteria for occipital nerve ablation for severe cancer pain due to malignancy involving the head and neck.

Removed HCPCS code K1023 from the applicable codes list.

Updated Description of Services, Clinical Evidence, FDA, and References sections to reflect the most current information.

1 statestate-specific (Kentucky)

InterQualInterQual referenced

Low-quality

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

evidence rating for GONB

−3.6 days/mopooled reduction in headache days

66%ONS complication incidence

1HCPCS codes removed

Coverage Criteria and Policy Position

Occipital nerve ablation for malignancy-related pain

Covered when meeting specific criteria:

Occipital nerve ablation for severe cancer pain due to malignancy involving the head and neck is governed by InterQual CP: Procedures, Neuroablation, Percutaneous.refer to InterQual

Coverage determined by InterQual criteria; see prior_auth module

Non-malignant occipital neuralgia and headache — not medically necessary / mixed

Policy conclusions for non-malignant occipital neuralgia and headache:

GONB diagnostic/therapeutic status: Injection of local anesthetics and/or steroids used as greater occipital nerve blocks: evidence is mixed — GONBs are not established as a specific diagnostic test for occipital neuralgia or headaches and efficacy for ON or cervicogenic headache is not established in well-designed trials; short-term symptom improvement has been reported in some studies.see document evidence summaries

Hayes and systematic reviews rate evidence as low-quality for chronic preventive use; may provide short-term benefit

Procedures considered unproven and not medically necessary: The following procedures are considered unproven and not medically necessary for diagnosing and/or treating occipital neuralgia or headaches due to insufficient evidence: neurostimulation or electrical stimulation, occipital neurectomy, partial posterior intradural C1-C3 rhizotomy, radiofrequency ablation (thermal or pulsed) or denervation, rhizotomy of C1-C3 spinal dorsal roots, surgical decompression of second cervical nerve root and ganglion, and surgical decompression of the greater occipital nerve.none

Explicit policy list of not medically necessary procedures

Coverage for short-term diagnostic/therapeutic GONB

Consider GONB covered when ALL of the following apply for a short-term diagnostic or therapeutic trial:

Short-term/diagnostic use: GONB is requested as a short-term diagnostic or therapeutic trial (not for indefinite maintenance chronic therapy).

Multiple reviews support short-term improvement but not long-term preventive benefit

Documented baseline and follow-up: Baseline headache frequency/severity and a follow-up assessment plan (for example headache diary and VAS/NPRS) are documented to evaluate response to the trial.

Trials and systematic reviews commonly required diaries and pain scores

Prior conservative therapy: Documented inadequate response or intolerance to standard acute and preventive headache therapies when GONB is proposed for prevention or repeated use.

Hayes and guideline panels recommend conservative management prior to procedural escalation

Not recommended for routine long-term preventive use

Consider GONB not routinely covered for long-term preventive therapy when ANY of the following apply:

Lack of long-term evidence: Request is for ongoing repeated GONB as long-term preventive therapy without enrollment in a clinical protocol or without robust long-term efficacy data.

Hayes and other reviews report little to no evidence of benefit for chronic use

Insufficient monitored trial response: No objective documented improvement after a monitored short-term trial (for example failure to achieve clinically meaningful response thresholds used in studies such as >=50% reduction in headache frequency or substantial VAS/NPRS improvement) to justify continued maintenance blocks.>=50% for positive trial (study-derived)

Several RCTs and reviews referenced responder thresholds of >=30% and >=50%

Coverage stance — procedural categories

Coverage depends on level of evidence and prior conservative management; evidence supports short-term benefit for GONB and variable benefit for RFA and surgical interventions in selected refractory patients.

GONB may provide short-term symptomatic relief for some headache types (including cluster headache and certain migraine contexts), but routine long-term benefit is not established.

Systematic reviews report short-term improvements with low-quality evidence for chronic preventive use

RFA/pulsed RFA: RFA and pulsed RFA report short-term pain reduction in observational studies and some trials, but high-quality long-term RCT evidence is limited and outcomes vary by technique and target; selection based on diagnostic blocks is frequently used in studies.

Meta-analyses and systematic reviews call for further well-designed trials

Surgical decompression/neurectomy/rhizotomy: Surgical approaches have reported clinically meaningful response rates in observational series, yet overall evidence quality is low and randomized trial validation is lacking; careful patient selection and documentation of prior therapies and diagnostic block response are recommended.

Observational meta-analyses show benefit but are limited by bias and heterogeneity

Selection and evidence considerations for neurostimulation

Evidence and typical candidate selection reported in literature

Typical candidate selection for neurostimulation: Candidates for permanent neurostimulation (ONS/PNS) are typically those who have failed conservative therapies and who demonstrate a successful temporary stimulation trial (commonly defined in the literature as >=50% reduction in pain or headache frequency).>=50% trial response

Derived from Hayes HTA and multiple study reports

Documentation and specialist involvement: Selection usually includes specialty evaluation (neurology or pain), documentation of baseline headache burden and prior treatment history, and recorded trial outcomes (frequency/intensity/responder rates).

Studies commonly reported baseline MMD, responder rates, and disability measures

PRF/RFA: evidence and uncertainty

Reported effectiveness and limitations for RFA/PRF

PRF/RFA evidence summary: Small prospective and observational studies report short-term effectiveness for pulsed RFA and conventional RFA in selected neuralgias and cluster headache; however, systematic reviews identify limited high-quality evidence, inconsistent RCT results, and methodological limitations leading to uncertainty about long-term clinical benefit.

Effectiveness rates reported in small studies (for example 50-77% for pulsed RFA) but require validation

Evidence and guideline synthesis

Summary of coverage-relevant findings and guideline positions from the reviewed literature and specialty societies:

Evidence summary for invasive neuromodulation: Evidence for invasive ONS/PNS is limited in quantity and quality (small case series, few RCTs); benefits are inconsistent and device-related complications (infection, lead issues, revisions) are substantial in some series.

Supports conservative approach and cautious use

Noninvasive neuromodulation: Some noninvasive neuromodulation (for example REN, supra-orbital TENS, eTNS, rTMS) shows low-to-moderate strength evidence in small trials for acute or preventive migraine, but overall evidence quality is poor to very poor across many modalities.

Consider per guidance where appropriate

Guideline positions: Professional societies generally recommend diagnostic blocks before RF neurotomy, reserve neurostimulation for medically refractory cases in tertiary centers or clinical studies, and state insufficient evidence to broadly recommend neuromodulation for many headache indications.

References include AAPM, ASPN, EHF, INS, and Congress of Neurological Surgeons

Guidance-derived coverage considerations

Summary of guidance-derived coverage considerations:

NICE conditional use and governance: Transcutaneous electrical stimulation of the supraorbital nerve (eTNS/SON) for acute migraine should be used with special arrangements for clinical governance, consent, audit/research; preventive use should be limited to research because evidence is inadequate.

Based on NICE 2022 recommendations

Neuromodulation and invasive procedures: Occipital nerve stimulation and other invasive neuromodulation procedures have limited long-term evidence; guidance recommends use only in medically intractable cases within tertiary centers or as part of valid clinical studies where governance and outcome monitoring are in place.

Reflects EHF, INS and NICE positions

Device and regulatory note: Procedures are not FDA-regulated but devices used are subject to FDA 510(k) or De Novo clearance; document device identifiers and product codes when applicable.

Operational documentation guidance

Occipital nerve ablation for cancer-related pain

Policy directs use of external clinical criteria for certain occipital nerve ablation indications

InterQual-based coverage: Occipital nerve ablation for severe cancer pain due to malignancy involving the head and neck: medical necessity is determined by InterQual CP: Procedures, Neuroablation, Percutaneous.Use InterQual

Policy removed prior statement that neurolytic occipital nerve ablation is proven and medically necessary for malignancy-related head/neck pain; now refer to InterQual.

The policy lists multiple surgical and ablative procedures as unsupported for routine diagnosis or treatment of occipital neuralgia or headache when evidence is insufficient. Specifically, the policy names occipital neurectomy, partial posterior intradural C1–C3 rhizotomy, radiofrequency ablation (thermal or pulsed) or denervation, rhizotomy of C1–C3 spinal dorsal roots, surgical decompression of the second cervical nerve root and ganglion, and surgical decompression of the greater occipital nerve as procedures the plan considers unproven or not medically necessary for these indications. These positions are grounded in the document’s statement that the available evidence is insufficient to conclude that surgery is effective for occipital neuralgia or cervicogenic headache and that long-term efficacy has not been established in well‑designed trials.

The policy states that repeated, indefinite greater occipital nerve blocks (GONB) as chronic preventive therapy are not supported by sufficient high‑quality evidence. Hayes assessments and randomized trials indicate that GONB may provide short‑term symptom improvement but that there is little to no evidence of benefit for routine long‑term preventive use

Surgical interventions (neurectomy, decompression, rhizotomy, dorsal root section and related procedures) report some favorable results in observational series, but the policy emphasizes that these are based on low‑quality, heterogeneous studies. Because well‑designed randomized controlled trials are lacking and long‑term outcomes are not established, the policy does not support assuming universally durable efficacy for these procedures and recommends careful patient selection, documentation of prior conservative therapy failure, and reliance on specialty evaluation before considering such surgeries.

The policy highlights that many applications of radiofrequency modalities (conventional RFA and pulsed RFA) and certain neurostimulation uses are supported primarily by small prospective series, retrospective studies, or reviews with methodological limitations. Where randomized controlled trials are absent, inconsistent, or of very low quality, the document characterizes these interventions as having uncertain clinical benefit. As a result, RFA/PRF applications without robust RCT evidence are considered investigational or not medically necessary outside well‑defined study settings or clearly selected refractory populations.

Professional guidance cited in the policy (European Headache Federation, INS, and other bodies) recommends that invasive neuromodulation devices and implantation procedures be restricted to specialized settings. The policy therefore indicates that implantable neuromodulation (e.g., occipital nerve stimulation) should be used only for medically intractable syndromes within tertiary headache centers, or as part of valid clinical studies, and only after documented failure of conservative therapies and appropriate trial stimulation when applicable.

The policy references NICE guidance that certain invasive procedures should only be delivered under defined governance arrangements. For example, NICE advises that procedures such as transcutaneous supraorbital nerve stimulation and implantation procedures for cluster headache be provided only with special arrangements for clinical governance, consent, audit, and research. The policy adopts this position by indicating such procedures are appropriate primarily in contexts that include audit, governance, and research oversight rather than routine community practice.

The policy history documents a material change: prior affirmative language claiming that neurolytic occipital nerve ablation was "proven and medically necessary" for pain due to malignancy involving the head and neck was removed. In its place, the policy now instructs use of external clinical criteria (InterQual CP: Procedures, Neuroablation, Percutaneous) to determine medical necessity for occipital nerve ablation in severe cancer‑related head and neck pain.

The policy describes three broad intervention types relevant to occipital neuralgia and related headaches. Injection therapy (GONB) involves injection of a local anesthetic with or without steroid at the greater occipital nerve for diagnostic or short‑term therapeutic purposes. Neurostimulation (ONS/PNS and transcutaneous/external modalities) encompasses implantable electrode systems requiring trial stimulation and noninvasive devices such as eTNS or REN; evidence and regulatory status vary by device. Ablative procedures (RFA/PRF and neurolytic agents) involve thermal or pulsed radiofrequency lesioning or chemical neurolysis intended to provide longer‑duration pain relief, but techniques and durability differ across studies and indications.

The policy reiterates that continued repeated GONB for chronic migraine prevention without documented benefit from an initial monitored short‑term trial is not supported. Specifically, ongoing maintenance blocks should be preceded by a documented trial that demonstrates objective improvement (for example reductions in headache days or pain scores as documented in a headache diary); without such documented response and failure of standard preventive therapies, repeat GONBs for prevention may be considered not medically necessary.

Surgical procedures for occipital neuralgia or cervicogenic headache that lack documentation showing prior conservative therapy failure, absence of alternative diagnoses, or lack of a positive diagnostic block are unlikely to meet medical necessity criteria. The policy explains that because the evidence base for surgery is limited and long‑term benefit is not established in randomized trials, surgery without documented prior conservative management and appropriate diagnostic evaluation may be excluded from coverage.

Where randomized trials have failed to show benefit or the available RCTs are inconsistent or poor quality, the policy states that use of RFA/PRF or neurostimulation for those headache types is not supported. Interventions for which RCTs demonstrate no benefit or provide very low‑quality evidence may be considered investigational or not medically necessary unless used in clearly defined research or tertiary‑center contexts with robust documentation.

The policy cautions that routine invasive occipital nerve stimulation (ONS) for chronic cluster headache or chronic migraine is not broadly supported by high‑quality evidence. Given small, low‑quality RCTs and observational series reporting device‑related complications, the policy treats routine implantation as experimental or investigational for many indications and emphasizes that ONS should generally be reserved for selected, refractory patients in specialized settings or research protocols.

Consistent with NICE 2022 guidance, the policy notes that preventive use of transcutaneous supraorbital nerve (SON) stimulation currently has inadequate evidence and therefore should be restricted to research settings. For acute treatment, NICE allows use only with special arrangements for governance and audit; for preventive use the recommendation is research‑only until higher‑quality evidence becomes available.

As noted in the policy’s revision history, the prior affirmative statements asserting that neurolytic occipital nerve ablation was proven and medically necessary for malignancy‑related head and neck pain were removed. The updated policy instead directs clinicians and reviewers to InterQual neuroablation criteria for determinations of medical necessity in this cancer‑related indication.

Applicable Codes and Coding Notes

Applicable CPT/HCPCS/ICD-10 Codesmixed

63185	Laminectomy with rhizotomy; 1 or 2 segments.
63190	Laminectomy with rhizotomy; more than 2 segments.
64405	Injection(s), anesthetic agent(s) and/or steroid; greater occipital nerve.
64553	Percutaneous implantation of neurostimulator electrode array; cranial nerve.
64555	Percutaneous implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve).
64568	Open implantation of cranial nerve (e.g., vagus nerve) neurostimulator electrode array and pulse generator.
64570	Removal of cranial nerve (e.g., vagus nerve) neurostimulator electrode array and pulse generator.
64575	Open implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve).
64590	Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver.
64596	Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; initial electrode array.

1–10 of 24
1/3

Procedure/diagnosis codes — not listedmixed

Not provided in this excerpt

No explicit CPT/ICD codes are listed in this document portion.

Codes referenced in excerptmixed

No codes listed

RFA device product codesmixed

GXD	FDA product code for radiofrequency lesion generators
GXI	FDA product code for radiofrequency lesion probes

Electrical stimulation device product codes and examplesmixed

GZF	FDA product code for certain electrical stimulation devices
GZB	FDA product code for certain electrical stimulation devices
PCC	FDA product code for certain electrical stimulation devices
K203181	FDA 510(k)/De Novo identifier associated with Nerivio Migra

Removed HCPCS CodesHCPCSNot Covered

K1023

HCPCS code K1023 (removed from applicable codes)

Clinical trial baseline headache frequency

Baseline headache days (trial example)Approximately 23.4 headache days per month (active group in cited chronic migraine trial).

Baseline migraine days (trial example)Approximately 15.6 migraine days per month (active group in cited chronic migraine trial).

Study duration12‑week active treatment period with weekly blocks described in the trial example.

Population noteStudy population excluded individuals with history of 2–4 preventive treatment failures, limiting generalizability.

Success definition for pulsed RFA (study-specific)

Provider Actions, Prior Authorization, and Documentation

Prior Authorization
Prior authorization likely required for chronic use
Prior authorization is likely required for repeated or chronic use of greater occipital nerve blocks (GONB) and other device-based or implantable therapies. Requests for ongoing or maintenance treatments should include documentation of prior conservative therapies and justification for continued therapy given limited evidence of long‑term benefit for chronic use.
Prior authorization recommended for chronic/repeat GONB or device-based chronic therapy requests

Prior Authorization
Prior authorization for RFA/pulsed RFA
Requests for radiofrequency ablation (RFA) or pulsed RFA (PRF) generally require prior authorization. Provide the diagnosis, prior conservative care tried and failed, imaging or procedural documentation as applicable, and objective pre‑ and post‑procedure outcomes. Because RFA/PRF evidence is heterogeneous and long‑term benefit is uncertain, stronger documentation of clinical necessity is expected.
Include diagnosis, prior conservative therapies and durations, and rationale for RFA/PRF technique chosen (thermal vs pulsed)
Provide outcome measures and follow‑up data when available

Conservative Treatment and Step Therapy Expectations

Conservative medication therapy referenced — duration not specified

Conservative medication therapy referenced but no explicit duration or mandatory trial requirements provided in this part.

Conservative medication therapy: Oral analgesics and antiinflammatory agents are described as effective for some individuals and are referenced as first-line treatments prior to injections or more invasive interventions.

No explicit duration or mandatory trial specified in this policy excerpt

Prior trial of guideline-directed medical therapies before repeated/maintenance GONB

Prior trial of guideline-directed medical therapies before repeated/maintenance GONB is expected:

Prior guideline-directed medical therapy: Documented inadequate response or intolerance to standard acute and preventive migraine therapies is expected before approval of repeated or maintenance GONB.

Hayes and systematic reviews recommend conservative therapy prior to repeated GONB

Frequency, Repeat Procedures, and Limits

GONB — literature reports repeated blocks; policy frequency limit absent

Repeated GONB in literatureMeta‑analyses and trials report repeated GONBs in study protocols (eg, repeated weekly injections in chronic migraine trials and short‑term PDPH studies).

Policy frequency limitNo explicit policy frequency limit for repeated GONB is stated in this excerpt.

Short‑term benefit windowEvidence supports short‑term therapeutic effect (for PDPH up to 24 hours; chronic migraine trials show benefit over 12 weeks), suggesting protocols often use repeated blocks over weeks with reassessment.

GONB trial protocols and reassessment

Common trial protocolsPublished trials commonly administered 1–4 weekly GONB injections with scheduled reassessment (eg, weekly injections for 4–12 weeks).

Reassessment expectation

Imaging and Procedural Guidance

Documentation Required
Document imaging guidance for neurolytic/destructive procedures
For neurolytic or destructive procedures coded with imaging guidance (e.g., destruction by neurolytic agent, paravertebral facet joint nerve(s)), document the imaging guidance used (fluoroscopy or CT) when relevant.
Specify imaging modality and technique on procedural documentation and claims.

Documentation Required
GONB: image guidance optional — document if used
For GONB, imaging is optional; if image guidance (such as ultrasound) is used, document it in the procedure note.
Note ultrasound or other imaging used to localize the occipital nerve when applicable.

Documentation Required
Document use of fluoroscopy or CT for RFA/PRF and C2 DRG procedures

Definitions and Terminology

Cervicogenic headache and occipital neuralgia are described as pain syndromes thought to arise from impingement, entrapment, or dysfunction of occipital nerves or upper cervical structures; clinical presentations commonly include unilateral posterior head and neck pain and may be associated with radicular symptoms. Management spans conservative medical therapy, diagnostic and therapeutic nerve blocks, radiofrequency neurotomy, neurostimulation, and surgical options; however, the policy emphasizes that the evidence base varies widely across interventions and that many invasive procedures lack high‑quality RCT support.

Cervicogenic Headache definition

Cervicogenic headache definitionReferred pain perceived in the head from a source in the neck; caused by disorder of the cervical spine and its bony, disc, or soft tissue elements.

Source attributionDefinition cited from the American Migraine Foundation (2016).

Clinical relevanceCervicogenic headache is distinguished from occipital neuralgia and informs differential diagnosis and treatment selection.

Neurectomy definition

Not Covered / Experimental Procedures

The policy’s not‑covered list explicitly identifies neurostimulation or electrical stimulation for occipital neuralgia/headache, occipital neurectomy, rhizotomy, and radiofrequency ablation (thermal or pulsed) among procedures deemed unproven or not medically necessary for routine use in these conditions. This reflects the document’s synthesis that the available studies are limited, inconsistent, or methodologically flawed and therefore insufficient to establish broad coverage for these interventions outside specified, evidence‑based or research contexts.

Clinical Evidence, Guideline References, and Rationale

Across the evidence synthesis the policy describes the overall quality of the literature as low to very low for many interventional modalities. Multiple systematic reviews, HTAs, and guideline statements highlight small sample sizes, heterogeneous patient populations, short follow‑up, methodological limitations, and variable results. Randomized controlled trials are sparse or inconsistent for RFA/PRF and many neurostimulation indications; safety signals (infections, lead migration, revision rates) are reported for implantable devices. Given these limitations, the policy supports short‑term diagnostic or therapeutic use for some injections but urges caution and restricted use, governance, or research enrollment for many invasive procedures.

The policy references multiple professional and health‑technology bodies to inform coverage considerations. These include the European Headache Federation, which restricts neurostimulation to tertiary centers and research contexts; the International Neuromodulation Society recommendations on appropriate neuromodulation use; NICE guidance on special arrangements for transcutaneous SON stimulation; and HTA findings (Hayes) and society guidance (AAPM, ASPN, Congress of Neurological Surgeons) that emphasize limited evidence and the need for diagnostic blocks and conservative therapy trials prior to invasive interventions.

Operational changes in this revision include removal of HCPCS code K1023 from the policy’s applicable codes list and an explicit instruction that medical necessity determinations for occipital nerve neuroablation in severe cancer‑related head and neck pain should follow the InterQual CP: Procedures, Neuroablation, Percutaneous criteria. The revision history documents removal of prior language that had characterized neurolytic occipital nerve ablation as proven for malignancy‑related pain and redirects reviewers to InterQual for those determinations.

Policy Summary

PayerUnitedHealthcare

PolicyOccipital Nerve Injections and Ablation (Including Occipital Neuralgia and Headache) (for Kentucky Only)

Policy CodePolicy CS086KY.11

Change TypeMaterial revisions and code removal

Effective DateNov 1, 2024

Next Review DateN/A

Key ActionFor occipital nerve ablation for severe cancer pain, use InterQual CP: Procedures, Neuroablation, Percutaneous for medical necessity determinations.

SourceLink

On This Page

Appropriate indication: Indication aligns with conditions for which short-term benefit is supported in the literature (for example acute migraine, cluster headache, cervicogenic headache, or PDPH).

Evidence strength varies by condition

Responder threshold (study-specific)Defined as ≥50% pain reduction at specified follow‑up timepoints (used as success in C2 DRG pulsed RFA and other PRF/RFA studies).

Timepoint exampleSix‑month success defined as ≥50% pain relief in Lee et al. (C2 DRG pulsed RFA).

Relation to prior block responseSuccessful PRF/RFA outcomes more likely when there was a prior ≥50% response to diagnostic block.

Responder thresholds used in literature

Common responder thresholdsLiterature commonly reports responder definitions of ≥30% and ≥50% reduction in headache days or pain intensity.

Example (30%)Some neurostimulation studies report ≥30% reduction in mean monthly migraine days as a meaningful responder outcome (eg, 10 kHz SCS data).

Example (50%)ONS/PNS and RFA/PRF studies frequently use ≥50% reduction to define clinical success for trial selection and primary endpoints.

Use of external criteria — InterQual reference

External criteria referencedRefer to InterQual CP: Procedures, Neuroablation, Percutaneous for medical necessity determinations for occipital nerve neuroablation (cancer‑related indications).

Policy change notePolicy removed prior statement that neurolytic occipital nerve ablation is proven and medically necessary for malignancy‑related head/neck pain and now defers to InterQual.

Operational implicationWhen InterQual criteria apply, follow those for prior authorization and coverage decisions; if not applicable, use UnitedHealthcare criteria as directed.

Documentation Required
Prior authorization typically requires documented trial response
Prior authorization commonly requires documented positive response to a diagnostic or temporary trial before approving continued or permanent therapy (for example, a temporary neurostimulation trial before permanent occipital nerve stimulator implantation). Documentation should show magnitude and duration of trial response.
Document objective trial response (commonly ≥50% pain reduction) and duration
Include headache diaries, baseline frequency, and follow‑up pain scores

Prior Authorization
Prior authorization for implantable neurostimulation
Prior authorization is required for requests for implantable neurostimulation (ONS, peripheral nerve stimulators, cervical SCS, etc.). Provide specialty consultation notes, prior conservative management, details of any temporary trial and response, and device/lead history. Given risk of complications and limited high‑quality long‑term evidence, careful selection and documentation are necessary.
Specify device type, trial details, responder status, and prior surgical/device history
Document specialty involvement (pain or neurology) and rationale for implantation

Billing Rule
Device‑based procedures — administrative note
Device‑based procedures and implants are administrative coverage decisions: the procedure itself is not regulated by FDA but devices used are subject to FDA 510(k)/De Novo/PMAs. Inclusion of codes in this policy does not guarantee payment. Claims must include applicable procedure and diagnosis codes and supporting documentation.
Devices used in RFA and electrical stimulation are FDA‑regulated; procedures are not
Listing of codes in policy is for reference only and does not guarantee coverage

Denial Risk
Unproven / Not Medically Necessary Procedures
The following procedures/interventions are identified in this policy as unproven or not medically necessary because of insufficient evidence and are likely to be denied: neurostimulation/electrical stimulation for many indications without robust evidence or governance, occipital neurectomy, partial posterior intradural C1–C3 rhizotomy, RFA (thermal or pulsed) or denervation for certain headache indications, rhizotomy of C1–C3 dorsal roots, and surgical decompression of occipital nerves for routine use outside well‑defined indications or governance arrangements.
List of unproven/not medically necessary procedures as described in policy

Denial Risk
Evidence limitations may affect coverage
Evidence limitations and low quality in many studies of GONB, RFA/PRF, surgical procedures, and neurostimulation may affect coverage decisions. Requests lacking robust supporting evidence, objective outcomes, or prior conservative therapy documentation are at higher risk for denial.
Evidence limitations (small studies, inconsistent RCTs, low quality) may lead to additional documentation requests or denial

Denial Risk
Evidence insufficiency for surgery
The evidence for surgical interventions (occipital neurectomy, nerve decompression, cervical dorsal rhizotomy, etc.) is insufficient and inconsistent. Prior authorization reviewers will expect detailed documentation of prior non‑surgical management and rationale for surgery given limited high‑quality long‑term data.
Surgical requests should document failure of conservative care and specialty consultation
Provide long‑term outcome expectations and complication counseling documentation

Denial Risk
Interventions lacking high‑quality randomized trial evidence
Many PRF/RFA and neurostimulation studies are small, observational, or have high risk of bias. Interventions lacking high‑quality randomized trial evidence require stronger individualized justification and objective outcome tracking when requested for coverage.
Document study‑level limitations when relying on literature for justification
Provide patient‑specific rationale and outcomes data

Denial Risk
Insufficient evidence may trigger denial for ONS and similar implants
For therapies with limited evidence (including ONS and some neurostimulation applications), insufficient or low‑quality data may trigger denial. Submit comprehensive documentation of prior therapies, objective outcome measures, device history, and complication risk discussion to support clinical necessity.
Insufficient evidence for long‑term benefit may lead to denial without strong documentation

Documentation Required
Special arrangements and governance
Procedures that NICE or other authorities recommend only with special arrangements (clinical governance, consent, audit, or research) should follow those governance expectations. Prior authorization may request evidence of local governance, informed consent detailing uncertainties, and participation in outcome monitoring or registries.
If applicable, supply documentation of clinical governance arrangements, consent language, and audit/registry participation

Documentation Required
Prior response and specialty care
Prior authorization requests should document prior response to diagnostic blocks or temporary procedures and involvement of appropriate specialties (e.g., pain medicine, neurology, neurosurgery). Include records of prior diagnostic block results, imaging, and specialty consult notes.
Include prior diagnostic block results, specialty consultation, and imaging when applicable

Prior Authorization
Selection for permanent ONS implantation typically requires documented positive trial
Selection for a permanent occipital nerve stimulation (ONS) implant typically requires a documented positive temporary trial (commonly ≥50% improvement) and follow‑up outcome data. Authorization reviewers expect clear trial documentation, responder definition, and plan for long‑term monitoring and device management.
Temporary trial documentation (magnitude and duration of response) is required for permanent implantation requests
Provide plan for follow‑up and management of complications

Documentation Required
Documentation and governance
Ensure documentation and governance items are submitted with requests: informed consent addressing uncertainties and risks, baseline and follow‑up headache metrics (diaries, headache‑day counts), responder rates, adverse events, prior device revision/infection history, and specialty sign‑off. Audit and research participation may be requested when procedures are recommended under special arrangements.
Provide baseline and follow‑up headache‑day metrics, responder rates, and adverse events
Include informed consent and documentation of prior device complications or revisions

Note
When deciding coverage, providers must reference benefit requirements
When deciding coverage, providers must reference the member's federal, state, or contractual benefit requirements; this policy provides guidance but the applicable benefit terms govern. UnitedHealthcare uses InterQual for neuroablation determinations where applicable.
Verify member‑specific plan benefits and any state/federal mandates before proceeding
InterQual criteria may be applied for occipital nerve ablation for cancer pain

Step Therapy
Conservative therapies should be attempted first
Conservative therapies (oral analgesics, antiinflammatories, behavioral therapies, and other noninvasive measures) should be attempted and documented before escalating to invasive procedures. Provide duration and response to these therapies in prior authorization submissions.
Document trials of standard medical therapies and noninvasive interventions and their durations
Conservative therapy documentation is expected prior to repeat GONB, RFA/PRF, or neurostimulation

Step Therapy
Conservative‑first implication for GONB
For therapeutic greater occipital nerve blocks (GONB), expect short‑term benefit with need for reassessment prior to repetition. Prior authorization for repeated GONB will require documentation of prior benefit, treatment intervals, and plans for further management if short‑term relief is not sustained.
Therapeutic GONB typically provides short‑term relief; document prior benefit and timing of repeat injections

Note
Studies and reviews emphasize use of PRF but evidence is limited
Several studies and reviews emphasize consideration of pulsed radiofrequency (PRF) as a less destructive option, but evidence is limited. When PRF is proposed, prior authorization should include rationale for PRF over thermal RFA, prior treatment failures, and available outcome data.
State why PRF is chosen and include prior conservative care and outcome measures

Step Therapy
Conservative therapy before invasive procedures
Invasive procedures (surgical decompression, RFA/PRF, implants) should generally be reserved for patients refractory to conservative therapy per guideline recommendations (NICE, AAPM, AIHS). Prior authorization reviewers will expect documentation that noninvasive and medical therapy options were tried and failed.
Document trials of medical therapy, behavioral interventions, and less invasive interventional options before approving invasive procedures

Documented failure or inadequate response to conservative management and/or positive diagnostic block expected before surgery/ablation

Documented failure or inadequate response to conservative management and/or positive diagnostic block expected before surgery/ablation:

Conservative management failure and diagnostic block: Documented failure or inadequate response to conservative therapies and, when applicable, a positive diagnostic occipital nerve block or equivalent diagnostic testing is expected prior to considering surgical decompression, neurectomy, or dorsal root rhizotomy.

Studies report better outcomes when positive diagnostic block and specialty evaluation are documented

Documented failure of conservative treatments prior to consideration of PRF/RFA or neurostimulation

Documented failure of conservative treatments prior to consideration of PRF/RFA or neurostimulation:

Conservative therapy failure prior to PRF/RFA or neurostimulation: Prior conservative treatment failure should be documented before considering pulsed radiofrequency, conventional RFA, or implantable neurostimulation interventions.

Multiple studies and reviews emphasize PRF/RFA and neurostimulation are evaluated after conservative management failure

Positive temporary trial for permanent neurostimulation: For permanent neurostimulation implants, a successful temporary stimulation trial is typically required and is commonly documented as >=50% pain or headache frequency reduction during the trial period.>=50% trial response

Derived from Hayes HTA and RCT/series selection criteria

Conservative therapies and diagnostic blocks should be attempted prior to invasive neurostimulation or radiofrequency neurotomy

Conservative therapies and diagnostic blocks should be attempted prior to invasive neurostimulation or radiofrequency neurotomy:

Attempt guideline-recommended conservative therapies: Trials of guideline-recommended pharmacologic and behavioral preventive therapies should be attempted prior to invasive neurostimulation or radiofrequency neurotomy.

Guidelines (AAPM, ASPN, ASRN/AIHS panels) endorse conservative-first approaches

Diagnostic block prior to RFN: Diagnostic occipital nerve blockade should precede radiofrequency neurotomy when RFN is being considered to identify likely responders.

ASPN best-practice guidance recommends diagnostic blockade prior to RFN

Attempt guideline-recommended medical therapies before invasive neuromodulation or ablative procedures

Attempt guideline-recommended medical therapies before invasive neuromodulation or ablative procedures:

Guideline-recommended medical therapies attempted: Usual treatment options for migraine (acute: analgesics, triptans, antiemetics; preventive: beta blockers, calcium‑channel blockers, tricyclics, antiepileptics, CGRP inhibitors, botulinum toxin where indicated) should be attempted and documented before invasive neuromodulation or ablation is considered.

NICE and other guidance reserve invasive procedures for medically refractory cases

(Reserved) — additional conservative requirement items

Reserved additional conservative requirements: (Reserved) Additional conservative treatment requirement items as specified by InterQual or plan‑specific utilization management rules.

Policy references InterQual for specific neuroablation requirements and plan documents may define further steps.

Protocols include planned follow‑up to document baseline and post‑block headache metrics (headache diary, VAS/NPRS) to assess response.

No standardized long‑term frequencyNo standardized long‑term maintenance frequency is established in the excerpt; continuation typically depends on documented short‑term benefit and prior conservative therapy.

Frequency for GONB, RFA/pulsed RFA — not specified

Frequency specification in excerptFrequency for GONB, RFA, or pulsed RFA is not explicitly specified in this excerpt.

Study‑level schedulesSome studies repeat blocks or perform single PRF/RFA with variable reported durations of benefit, but no uniform interval for repeats is provided.

Clinical implicationDecisions on repeat procedures should be guided by documented trial response and applicable external criteria (eg, InterQual) rather than a fixed frequency in this policy excerpt.

Frequency details — not specified in excerpt (placeholder)

Frequency details not providedNo frequency details specified in this excerpt for other procedures; refer to external criteria or full policy for procedure‑specific limits.

Use InterQual when applicableFor occipital nerve neuroablation related to cancer pain, InterQual criteria should be used and may contain frequency or repeat‑procedure guidance.

Documentation guidanceWhen repeat procedures are requested, document baseline and follow‑up outcomes, prior conservative therapy, and prior trial response.

Occipital radiofrequency neurotomy and neurostimulation — repeat sessions discussed

Repeat RFN sessions in literatureSeveral studies document repeat RFN sessions and report relief durations up to approximately 6 months in some series.

No explicit repeat limitsThe excerpt discusses repeat RFN but provides no explicit policy limits on number or interval of repeat sessions.

Imaging/technique noteGuidance recommends diagnostic blockade before RFN and ruling out other etiologies with MRI/CT; ASPN notes lesioning time settings and need for further study to define repeat recommendations.

Radiofrequency ablation — device administrative note

Administrative/device noteRFA is a procedure (not FDA‑regulated) but devices used are regulated; FDA product codes GXD (generators) and GXI (probes) are noted for administrative tracking.

Implication for claimsDocument device product codes and device details when applicable for administrative and prior authorization purposes.

No frequency guidanceThis device‑related note does not specify clinical frequency limits for RFA procedures.

Refer to InterQual for frequency limits for neuroablation procedures

Refer to InterQual for neuroablation frequencyWhen assessing medical necessity and possible frequency limits for neuroablation procedures (including occipital nerve ablation), refer to InterQual CP: Procedures, Neuroablation, Percutaneous.

Policy revision notePolicy now directs use of InterQual criteria for occipital nerve ablation in severe cancer pain cases; prior HCPCS code K1023 was removed.

Operational implicationIf InterQual criteria are not applicable, follow UnitedHealthcare policy and document baseline/follow‑up outcomes and prior conservative therapy.

Procedures such as RFA, pulsed RFA, and C2 dorsal root ganglion procedures frequently use fluoroscopy or CT for target localization; include imaging modality in the request and operative note.

Report fluoroscopy/CT guidance and any imaging findings relevant to selection or outcome.

Documentation Required
CT or ultrasound commonly used for PRF/RFA targeting cranial/ganglion structures — document
Published PRF/RFA studies targeting cranial ganglia or deep structures often used CT or ultrasound guidance; include modality and justification when submitting documentation.
Indicate CT or ultrasound guidance and any procedural safety precautions taken.

Documentation Required
Obtain MRI/CT to rule out other causes before RF neurotomy; document findings
Before occipital radiofrequency neurotomy, imaging (MRI and/or CT) is recommended to rule out other causes; include imaging reports in prior authorization or surgical planning documentation.
Attach MRI/CT reports that exclude alternative etiologies when available.

Documentation Required
Provide imaging and procedural details for implantation, RFA, and pulsed RF
For implantations, RFA, or pulsed RF targeting deep structures, imaging details may be required by reviewers; include procedural imaging and technique notes even when the policy does not specify exact imaging requirements.
Provide intraoperative imaging details and any device identifiers.

Prior Authorization
If InterQual applies, follow its imaging and procedural specifications
Fallback note: when InterQual or UnitedHealthcare criteria apply (or when InterQual does not have criteria), those tools will specify imaging and procedural requirements; include InterQual findings or alternate UnitedHealthcare criteria with the request.
If InterQual applies, submit InterQual determination or evidence showing member meets InterQual criteria.

Neurectomy definitionPartial or total excision or resection of a nerve.

Evidence noteOccipital neurectomy and decompression procedures have insufficient high‑quality trial evidence to confirm long‑term efficacy for headaches.

Policy stanceSurgical neurectomy is listed among procedures considered unproven/not medically necessary for routine treatment of occipital neuralgia/headaches in this excerpt.

Rhizotomy definition

Rhizotomy definitionSurgical section of a nerve root to relieve pain.

Context noteRhizotomy (eg, C1‑C3 dorsal root procedures) is included among invasive surgical options with limited RCT evidence for headache indications.

Policy implicationRhizotomy is considered an invasive option with insufficient high‑quality evidence for routine coverage in many headache indications.

Intervention failure definition (from PDPH GONB meta‑analysis)

Intervention failure (PDPH meta‑analysis)Defined as repeated GONBs, use of analgesics, or the need for an epidural blood patch in the reviewed PDPH studies.

Study scopeChang et al. (2021) included seven studies (four RCTs and three non‑RCTs) totaling 275 adults when assessing GONB for PDPH.

Outcome timeframeMeta‑analysis reported therapeutic effect up to 24 hours post‑procedure with short follow‑up durations noted as a limitation.

GONB (Greater Occipital Nerve Block) definition

GONB definitionInjection of local anesthetic with or without steroid at the greater occipital nerve for diagnostic or therapeutic purposes in headache disorders.

Use casesUsed as short‑term diagnostic or therapeutic trial in migraine, cervicogenic headache, cluster headache, and PDPH in studies.

Evidence noteEvidence supports short‑term symptomatic relief; long‑term preventive efficacy is not established.

RFA (Radiofrequency Ablation) definition

RFA definitionThermal or pulsed radiofrequency lesioning of occipital nerves or related ganglia intended to provide prolonged pain relief; devices used are regulated by FDA 510(k) processes.

Technique variantsIncludes conventional thermal RFA and pulsed radiofrequency (PRF/PRFT); time/lesion settings vary across studies.

Evidence notePublished studies report variable short‑term benefits; well‑designed RCTs and longer follow‑up are needed to define long‑term effectiveness.

Occipital nerve decompression/neurectomy definition

Occipital nerve decompression/neurectomy definitionSurgical procedures to decompress or remove portions of occipital nerves to relieve occipital neuralgia or migraine related to occipital nerve pathology.

Outcome evidenceMeta‑analyses and case series report high reported response rates (eg, >50% improvement in many studies) but overall evidence quality is low and mostly retrospective.

Policy implicationSurgical decompression/neurectomy outcomes are promising in selected series but lack high‑quality RCT confirmation; careful selection required.

Positive trial definition

Positive trial definitionTemporary stimulation trial demonstrating a responder effect commonly defined as ≥50% reduction in pain or headache frequency; used to select candidates for permanent implantation.

Usage in studiesMost ONS implant studies selected patients after a successful temporary trial (typically ≥50% reduction lasting weeks).

Documentation expectationSelection for permanent implants is typically documented by trial response and measured follow‑up outcomes (headache days, VAS/NPRS).

ONS / PNS definition

ONS/PNS definitionImplantation of electrodes to stimulate the occipital or peripheral nerves for prevention or treatment of headache disorders; devices are regulated by FDA 510(k).

Clinical useUsed for chronic migraine, refractory cluster headache, and other refractory headache syndromes in selected patients; trial periods commonly precede permanent implantation.

Safety considerationsStudies report device‑related complications (lead issues, infection) and possible need for revision surgery.

Transcutaneous or external neurostimulation definition

Transcutaneous/external neurostimulation definitionNoninvasive electrical stimulation modalities applied externally (eg, tONS, TENS, REN, eTNS) for acute or preventive migraine therapy.

Typical applicationDevices are self‑administered (eg, headband/patch); stimulation sessions vary by device (eg, 1–2 hours for acute, 20 minutes for prevention per NICE eTNS description).

Evidence noteEvidence quality varies; NICE and systematic reviews recommend conditional use or research‑only contexts for some applications.

Transcutaneous electrical stimulation (eTNS / SON) definition

eTNS / SON stimulation definitionNoninvasive stimulation of the supraorbital nerves via skin electrodes (headband/patch) applied to the forehead to treat or prevent migraine; typically daily self‑administered sessions.

Session examplesStimulation applied daily: about 1–2 hours during an acute attack or ~20 minutes for preventive sessions as described by NICE.

Regulatory/evidence contextNICE reviewed RCTs and case series and recommends conditional provision with governance or research for prevention.

Radiofrequency ablation (RFA) procedural note

RFA procedural noteRFA uses lesion generators and probes (FDA product codes GXD and GXI); procedural parameters (eg, lesion duration, number) vary across studies and affect outcomes.

Regulatory noteRFA procedure is not FDA‑regulated, but devices used are subject to FDA 510(k) clearances; document device identifiers when relevant.

Clinical recommendationDiagnostic occipital nerve blockade generally precedes RF neurotomy per ASPN guidance; imaging (MRI/CT) is recommended to rule out other etiologies before RFN.

InterQual neuroablation criteria reference

InterQual neuroablation referenceInterQual CP: Procedures, Neuroablation, Percutaneous — referenced by UnitedHealthcare for determining medical necessity for occipital nerve ablation (especially cancer‑related indications).

Policy instructionPolicy instructs referring to InterQual criteria for neuroablation decisions and removed previous language asserting neurolytic ablation as proven for malignancy‑related pain.

Operational implicationUse InterQual for prior authorization and medical necessity determinations where applicable; otherwise follow UnitedHealthcare policy guidance.